- Tilray (TLRY) initiates roundtable with German regulators to kick off draft legislation to legalize adult-use cannabis in Germany
- Tilray Medical helps patients in need through safe and reliable access to a global portfolio of medical cannabis brands
- In this meeting, the German Drug Commissioner, Burkhard Blienert, presented the plan for adult-use cannabis legalization
- Tilray Brands has been committed to producing the highest-quality cannabis products available to consumers and patients in need around the world
- Tilray Stock (TSX:TLRY) is down under 5 per cent, trading at C$4.21 at 1:27 pm EST
Tilray Brands (TLRY) has initiated a policy roundtable with German regulators on adult-use cannabis legalization in Germany.
Tilray Medical helps patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, and Symbios.
The German Drug Commissioner, Burkhard Blienert, presented the plan for adult-use cannabis legalization in this meeting.
With this event, Tilray reaffirms its leading role as a trusted partner to government regulators and contributes to German legalization efforts by sharing its long-standing expertise and experience in cannabis research, product quality and safety, supply management, patient and consumer protection, and cannabis education.
Denise Faltischek, Chief Strategy Officer and Head of International, Tilray Brands, Inc., said, “We are honoured to have initiated this high-level exchange on one of the world’s most important cannabis endeavours.”
“We applaud the German government in leading responsible adult-use cannabis legislation in Europe, and we are proud to support this effort,” added Faltischek.
Sascha Mielcarek, Managing Director, Tilray Europe, said, “As a market leader in Germany and Europe, our highest priority for a successful launch of an adult-use market in Germany is to lead with the highest quality-control standards that are consistent and reliable for consumers and patients.”
Tilray Brands has been committed to producing the highest-quality cannabis products available to consumers and patients in need worldwide and was the first to successfully export medical cannabis from North America and import medical cannabis products into the EU in 2016.
Tilray has made several strategic investments, resulting in first-mover advantages in Germany and Europe.
Tilray has grown to become an approved licensed producer of medical cannabis in Canada, building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany.